disturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia.

Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage clinical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of their strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes and to seek strategic partners for global commercialization.

The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.